Barclays raised the firm’s price target on Fate Therapeutics to $10 from $6 and keeps an Overweight rating on the shares after speaking with management post the Q4 report. The analyst sees an “encouraging catalyst path” for Fate and added lupus to the model.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on FATE:
- Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
- Fate Therapeutics Inc (FATE) Q4 Earnings Cheat Sheet
- Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Biotech Alert: Searches spiking for these stocks today
